We found that a combination of DCP-IL-12 and DCP-FLT3L (hereafter DCP-IL-12/FLT3L) achieved superior tumor control compared to DCPs expressing either cytokine alone in independent experiments (Fig. 2b), including studies with longer follow-up analysis (Extended Data Fig. 5a,b). Here, FLT3LG is linked to neoplasm.